Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC
The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in first-line treatment of elderly patients with advanced lung cancer who were unfit for polychemotherapy. Progression-free survival, response rate and overall...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2017-06, Vol.37 (6), p.3189 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | 3189 |
| container_title | Anticancer research |
| container_volume | 37 |
| creator | Mencoboni, Manlio Filiberti, Rosa Angela Taveggia, Paola Del Corso, Lisette Del Conte, Alessandro Covesnon, Maria Grazia Puccetti, Cheti Donati, Sara Auriati, Laura Amoroso, Domenico Camerini, Andrea |
| description | The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in first-line treatment of elderly patients with advanced lung cancer who were unfit for polychemotherapy. Progression-free survival, response rate and overall survival were secondary end-points.
Seventy-six patients received 50 mg of oral vinorelbine three times per week, until disease progression, patient refusal or unacceptable toxicity. Patients were evaluated for response and toxicity after one cycle of chemotherapy. The treatment was considered feasible with a grade 3/4 toxicity rate lower than 20%.
Clinical benefit was observed in 50% of patients. Median overall survival was 8.0 months. Grade 1/2 toxicity was observed in 53 patients (69.7%), grade 3 toxicity in eight patients (10.5%). One patient had grade 4 diarrhea.
Metronomic oral vinorelbine is safe in elderly patients, allowing for long-term disease stabilization with optimal patient compliance. |
| doi_str_mv | 10.21873/anticanres.11679 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_21873_anticanres_11679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28551663</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-fd9f95bf2b7309c1572dd5b8d7c15d0b3c98c1cd3fe81b2e968bf14b8dde738e3</originalsourceid><addsrcrecordid>eNpFkMtOwzAURC0EoqXwAWyQfyDFjus4XqKoPKRCkQpsI8e-bo1Sp7KNUP6e0PJYzSzmzOIgdEnJNKelYNfKJ6eVDxCnlBZCHqExFZJmgjNyjMYk5yQThPAROovxnZCikCU7RaO85JwWBRsjv1IWUo87i29diClrnQdcbWDbpQ0Etevxp0sb_AgpdL7bOo1Xzq9byNQafMLLoFr85nwXoG2-UefxvDUQ2h4_q-SGTTw8PK2qRXWOTqxqI1z85AS93s5fqvtssbx7qG4WmWazWcqskVbyxuaNYERqykVuDG9KI4ZuSMO0LDXVhlkoaZODLMrG0tkwMCBYCWyC6OFXhy7GALbeBbdVoa8pqffu6n939d7dwFwdmN1HswXzR_zKYl-Dem-U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Mencoboni, Manlio ; Filiberti, Rosa Angela ; Taveggia, Paola ; Del Corso, Lisette ; Del Conte, Alessandro ; Covesnon, Maria Grazia ; Puccetti, Cheti ; Donati, Sara ; Auriati, Laura ; Amoroso, Domenico ; Camerini, Andrea</creator><creatorcontrib>Mencoboni, Manlio ; Filiberti, Rosa Angela ; Taveggia, Paola ; Del Corso, Lisette ; Del Conte, Alessandro ; Covesnon, Maria Grazia ; Puccetti, Cheti ; Donati, Sara ; Auriati, Laura ; Amoroso, Domenico ; Camerini, Andrea</creatorcontrib><description>The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in first-line treatment of elderly patients with advanced lung cancer who were unfit for polychemotherapy. Progression-free survival, response rate and overall survival were secondary end-points.
Seventy-six patients received 50 mg of oral vinorelbine three times per week, until disease progression, patient refusal or unacceptable toxicity. Patients were evaluated for response and toxicity after one cycle of chemotherapy. The treatment was considered feasible with a grade 3/4 toxicity rate lower than 20%.
Clinical benefit was observed in 50% of patients. Median overall survival was 8.0 months. Grade 1/2 toxicity was observed in 53 patients (69.7%), grade 3 toxicity in eight patients (10.5%). One patient had grade 4 diarrhea.
Metronomic oral vinorelbine is safe in elderly patients, allowing for long-term disease stabilization with optimal patient compliance.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>DOI: 10.21873/anticanres.11679</identifier><identifier>PMID: 28551663</identifier><language>eng</language><publisher>Greece</publisher><subject>Administration, Metronomic ; Administration, Oral ; Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Phytogenic - administration & dosage ; Antineoplastic Agents, Phytogenic - adverse effects ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Disease-Free Survival ; Feasibility Studies ; Female ; Humans ; Italy ; Kaplan-Meier Estimate ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Medication Adherence ; Pilot Projects ; Time Factors ; Treatment Outcome ; Vinblastine - administration & dosage ; Vinblastine - adverse effects ; Vinblastine - analogs & derivatives</subject><ispartof>Anticancer research, 2017-06, Vol.37 (6), p.3189</ispartof><rights>Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-fd9f95bf2b7309c1572dd5b8d7c15d0b3c98c1cd3fe81b2e968bf14b8dde738e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28551663$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mencoboni, Manlio</creatorcontrib><creatorcontrib>Filiberti, Rosa Angela</creatorcontrib><creatorcontrib>Taveggia, Paola</creatorcontrib><creatorcontrib>Del Corso, Lisette</creatorcontrib><creatorcontrib>Del Conte, Alessandro</creatorcontrib><creatorcontrib>Covesnon, Maria Grazia</creatorcontrib><creatorcontrib>Puccetti, Cheti</creatorcontrib><creatorcontrib>Donati, Sara</creatorcontrib><creatorcontrib>Auriati, Laura</creatorcontrib><creatorcontrib>Amoroso, Domenico</creatorcontrib><creatorcontrib>Camerini, Andrea</creatorcontrib><title>Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in first-line treatment of elderly patients with advanced lung cancer who were unfit for polychemotherapy. Progression-free survival, response rate and overall survival were secondary end-points.
Seventy-six patients received 50 mg of oral vinorelbine three times per week, until disease progression, patient refusal or unacceptable toxicity. Patients were evaluated for response and toxicity after one cycle of chemotherapy. The treatment was considered feasible with a grade 3/4 toxicity rate lower than 20%.
Clinical benefit was observed in 50% of patients. Median overall survival was 8.0 months. Grade 1/2 toxicity was observed in 53 patients (69.7%), grade 3 toxicity in eight patients (10.5%). One patient had grade 4 diarrhea.
Metronomic oral vinorelbine is safe in elderly patients, allowing for long-term disease stabilization with optimal patient compliance.</description><subject>Administration, Metronomic</subject><subject>Administration, Oral</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents, Phytogenic - administration & dosage</subject><subject>Antineoplastic Agents, Phytogenic - adverse effects</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Disease-Free Survival</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Italy</subject><subject>Kaplan-Meier Estimate</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medication Adherence</subject><subject>Pilot Projects</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Vinblastine - administration & dosage</subject><subject>Vinblastine - adverse effects</subject><subject>Vinblastine - analogs & derivatives</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtOwzAURC0EoqXwAWyQfyDFjus4XqKoPKRCkQpsI8e-bo1Sp7KNUP6e0PJYzSzmzOIgdEnJNKelYNfKJ6eVDxCnlBZCHqExFZJmgjNyjMYk5yQThPAROovxnZCikCU7RaO85JwWBRsjv1IWUo87i29diClrnQdcbWDbpQ0Etevxp0sb_AgpdL7bOo1Xzq9byNQafMLLoFr85nwXoG2-UefxvDUQ2h4_q-SGTTw8PK2qRXWOTqxqI1z85AS93s5fqvtssbx7qG4WmWazWcqskVbyxuaNYERqykVuDG9KI4ZuSMO0LDXVhlkoaZODLMrG0tkwMCBYCWyC6OFXhy7GALbeBbdVoa8pqffu6n939d7dwFwdmN1HswXzR_zKYl-Dem-U</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Mencoboni, Manlio</creator><creator>Filiberti, Rosa Angela</creator><creator>Taveggia, Paola</creator><creator>Del Corso, Lisette</creator><creator>Del Conte, Alessandro</creator><creator>Covesnon, Maria Grazia</creator><creator>Puccetti, Cheti</creator><creator>Donati, Sara</creator><creator>Auriati, Laura</creator><creator>Amoroso, Domenico</creator><creator>Camerini, Andrea</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20170601</creationdate><title>Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC</title><author>Mencoboni, Manlio ; Filiberti, Rosa Angela ; Taveggia, Paola ; Del Corso, Lisette ; Del Conte, Alessandro ; Covesnon, Maria Grazia ; Puccetti, Cheti ; Donati, Sara ; Auriati, Laura ; Amoroso, Domenico ; Camerini, Andrea</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-fd9f95bf2b7309c1572dd5b8d7c15d0b3c98c1cd3fe81b2e968bf14b8dde738e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Metronomic</topic><topic>Administration, Oral</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents, Phytogenic - administration & dosage</topic><topic>Antineoplastic Agents, Phytogenic - adverse effects</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Disease-Free Survival</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Italy</topic><topic>Kaplan-Meier Estimate</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medication Adherence</topic><topic>Pilot Projects</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Vinblastine - administration & dosage</topic><topic>Vinblastine - adverse effects</topic><topic>Vinblastine - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mencoboni, Manlio</creatorcontrib><creatorcontrib>Filiberti, Rosa Angela</creatorcontrib><creatorcontrib>Taveggia, Paola</creatorcontrib><creatorcontrib>Del Corso, Lisette</creatorcontrib><creatorcontrib>Del Conte, Alessandro</creatorcontrib><creatorcontrib>Covesnon, Maria Grazia</creatorcontrib><creatorcontrib>Puccetti, Cheti</creatorcontrib><creatorcontrib>Donati, Sara</creatorcontrib><creatorcontrib>Auriati, Laura</creatorcontrib><creatorcontrib>Amoroso, Domenico</creatorcontrib><creatorcontrib>Camerini, Andrea</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mencoboni, Manlio</au><au>Filiberti, Rosa Angela</au><au>Taveggia, Paola</au><au>Del Corso, Lisette</au><au>Del Conte, Alessandro</au><au>Covesnon, Maria Grazia</au><au>Puccetti, Cheti</au><au>Donati, Sara</au><au>Auriati, Laura</au><au>Amoroso, Domenico</au><au>Camerini, Andrea</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>37</volume><issue>6</issue><spage>3189</spage><pages>3189-</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in first-line treatment of elderly patients with advanced lung cancer who were unfit for polychemotherapy. Progression-free survival, response rate and overall survival were secondary end-points.
Seventy-six patients received 50 mg of oral vinorelbine three times per week, until disease progression, patient refusal or unacceptable toxicity. Patients were evaluated for response and toxicity after one cycle of chemotherapy. The treatment was considered feasible with a grade 3/4 toxicity rate lower than 20%.
Clinical benefit was observed in 50% of patients. Median overall survival was 8.0 months. Grade 1/2 toxicity was observed in 53 patients (69.7%), grade 3 toxicity in eight patients (10.5%). One patient had grade 4 diarrhea.
Metronomic oral vinorelbine is safe in elderly patients, allowing for long-term disease stabilization with optimal patient compliance.</abstract><cop>Greece</cop><pmid>28551663</pmid><doi>10.21873/anticanres.11679</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2017-06, Vol.37 (6), p.3189 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_crossref_primary_10_21873_anticanres_11679 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Administration, Metronomic Administration, Oral Age Factors Aged Aged, 80 and over Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - adverse effects Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Disease-Free Survival Feasibility Studies Female Humans Italy Kaplan-Meier Estimate Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Male Medication Adherence Pilot Projects Time Factors Treatment Outcome Vinblastine - administration & dosage Vinblastine - adverse effects Vinblastine - analogs & derivatives |
| title | Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T17%3A05%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20First-line%20Chemotherapy%20with%20Metronomic%20Single-agent%20Oral%20Vinorelbine%20in%20Elderly%20Patients%20with%20NSCLC&rft.jtitle=Anticancer%20research&rft.au=Mencoboni,%20Manlio&rft.date=2017-06-01&rft.volume=37&rft.issue=6&rft.spage=3189&rft.pages=3189-&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/10.21873/anticanres.11679&rft_dat=%3Cpubmed_cross%3E28551663%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28551663&rfr_iscdi=true |